Kymera Therapeutics (KYMR) Cash & Equivalents (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Cash & Equivalents data on file, last reported at $144.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 60.16% year-over-year to $144.1 million in Q1 2026; TTM through Mar 2026 was $144.1 million, a 60.16% increase from a year earlier, with the FY2025 full-year figure at $357.0 million, up 196.88% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $144.1 million, down from $357.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for KYMR reached as high as $357.0 million in Q4 2025 and fell as low as $33.7 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $121.2 million across 5 years, with a median of $93.5 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 47.93% in 2023 and surged 396.68% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $68.4 million in 2022, then surged by 60.78% to $110.0 million in 2023, then rose by 9.36% to $120.3 million in 2024, then soared by 196.88% to $357.0 million in 2025, then slumped by 59.64% to $144.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $144.1 million in Q1 2026, $357.0 million in Q4 2025, and $112.9 million in Q3 2025.